Study that looked at the effect of different doses of PF-05221304 on the amount of fat in the liver
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety, Tolerability, and Pharmacodynamics of PF-05221304 Administered Daily for 16-Weeks to Adult Subjects With Nonalcoholic Fatty Liver Disease
Category & Conditions: Diabetes and Metabolic Disorders
Medicine: PF-05221304
ClinicalTrials.gov Identifier (NCT): NCT03248882
Protocol ID: C1171002
PrintDownloadOpen Plain Language Summary Result: Click here